Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: Biotech Jim who wrote (8231)	9/15/2000 9:10:19 AM
From: rkrw	Respond to of 9719

<<I would like to suggest that you look into two companies that may be suitable for the portfolio. These are picks and shovels types of companies, and they are DGEN and LEXG. Both have solid technology. I realize that most of the portfolio companies are drug discovery companies and/or get downstream royalties on any marketed products. These are somewhat different in that regard.>> Jim, at least in the case of LEXG, they're quickly moving downstream into drug development. Its press release of yesterday regarding utilizing affx gene chips highlights a few ares of focus internally, mainly oncology related. The recent ABGX deal points to an internal development platform as well. I liken their business model to ABGX, partner up the core technology for royalties while in parallel leverage into internal drug development. This will ultimately create a much more valuable company imo. Old buy MLNM partner strategy at work again.